{
    "success": true,
    "data": {
        "leverage": true,
        "derivatives": true,
        "swaps": true,
        "inverse": false,
        "replication_method": "synthetic",
        "ucits": false,
        "type": "ETP",
        "complex_factors": [
            "Leverage",
            "Synthetic Replication",
            "Compounding Effect",
            "Derivative Use",
            "Structured Product"
        ],
        "classification": "complex",
        "supporting_data": "The product is identified as 'Leverage Shares 2x Long Berkshire Hathaway (BRK-B) ETP Securities'. It is explicitly '2x Long', indicating significant leverage (2 times the daily performance), which far exceeds the temporary borrowing limits for UCITS and is a primary factor for complexity under MiFID II. The product's objective of providing 2x daily performance, along with its reference to a 'margin account' and 'Collateral Assets', strongly implies synthetic replication using derivatives such as swaps to achieve its leveraged exposure. The KID also explicitly warns, 'You are about to purchase a product that is not simple and may be difficult to understand.' It further details a 'Compounding Effect' due to 'daily leverage rebalancing', stating that holding the ETP for more than one day is likely to result in a return 'different to 2 times the return of the Reference Asset over that holding period,' which is magnified by more leverage and longer holding periods. This 'Compounding Effect' is a sophisticated concept that retail investors with basic knowledge are unlikely to fully grasp, especially its potential negative impact with higher volatility. The product is intended for 'sophisticated investors' who 'understand the risk of compounded returns and the increased risk of investment in leveraged products.' While the underlying asset (Berkshire Hathaway Class B shares) is transparent, the ETP's structure, relying on derivatives for leverage and subject to daily rebalancing and compounding, makes its performance dynamics opaque and complex for retail investors. As per the provided MiFID II rules, significant leverage, integral use of derivatives, and synthetic replication (implied by the structure) are key indicators of complexity. The ESMA guidance (CESR/09-295, point 7) states that 'all derivatives are assumed to be complex', and Art. 38(a) of the Level 2 Directive excludes instruments based on derivative contracts from being non-complex. The product is an ETP Security, not explicitly stated as UCITS, and its leveraged nature generally means it would not meet UCITS diversification and risk limits, thus it does not benefit from the UCITS presumption of non-complexity. The comprehension alert in the KID further confirms its complex nature."
    }
}